NCT06346912View on ClinicalTrials.gov

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

May 30, 2027

Study Completion Date

May 30, 2027

Conditions
Acute Lymphoblastic Leukemia,B-CellNon-hodgkin Lymphoma,B Cell
Interventions
BIOLOGICAL

CD19-BAFF Targeted CAR T-cells

Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion

Trial Locations (1)

310000

RECRUITING

The first affiliated hospital of medical college of zhejiang university, Hangzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER